The expression of STC2 is closely related to the prognosis of tumor patients, and its high expression leads to poor prognosis in patients with breast cancer (Esseghir et al., 2007), nasopharyngeal carcinoma (Lin et al., 2014), colorectal cancer (Ieta et al., 2009), and renal cell carcinoma (Meyer et al., 2009). The gene discussed is STC2; the disease is breast carcinoma.